Fig. 4

ShRNA PSMC5 alleviated cognitive impairment and motor disjunction, and improved synaptic structure in LPS-induced mice. A Results of the MWM test for shRNA PSMC5-treated mice, n = 15. B Results of the PAT test for shRNA PSMC5-treated mice, n = 15. C, D Motor coordination scores for shRNA PSMC5-treated mice. C Pole test score, n = 15. D Traction test score, n = 15. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to the control, saline, shRNA PSMC5, and VIPER groups; ^#P < 0.05, ^##P < 0.01 compared to the shRNA PSMC5 + LPS, VIPER + LPS, and shRNA PSMC5 + VIPER + LPS groups, analyzed by one-way ANOVA. Error bars indicate SEM. E Hematoxylin and eosin staining shows effect of shRNA PSMC5 on hippocampus neurons in LPS-induced mice. Representative photomicrographs of the hippocampus CA3 and CA4 area showing the histological changes of each group. n = 5 mice/group, n = 30 felds/group. F Transmission electron microscopy staining shows effects of shRNA PSMC5 treatment on synapses in the hippocampus. The green arrow shows the synaptic structure. n = 5 mice/group, n = 30 felds/group. G Effect of shRNA PSMC5 treatment on SYP and PSD95 levels in the mice brain. n = 3–4 mice/group